Skip to content

Study on the correlation between RBM15B levels and clinical characteristics of sepsis patients

Study on the correlation between RBM15B levels and clinical characteristics of sepsis patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116811
Enrollment
Unknown
Registered
2026-01-15
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis and its related encephalopathy

Interventions

Healthy Control Group:None
Sepsis patient group:sepsis

Sponsors

The First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Healthy Control Group (1) Age must be >= 18 years and = 18 years and = 2 points in SOFA score on the basis of suspected or confirmed infection; (3) The subject or their legal representative voluntarily participates in the study and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Healthy Control Group (1) Presence of acute infection or history of infection within the past 1 month; (2) History of or current clear central nervous system disease or severe psychiatric disorder; (3) Coexistence of malignancy, severe hepatic or renal dysfunction, or other severe chronic systemic diseases; (4) Long-term use of immunosuppressants, glucocorticoids, or biologics; (5) Pregnant or lactating females; (6) Other conditions deemed unsuitable for inclusion in the study by the investigator. 2. Sepsis Patient Group (1) History of clear central nervous system disease (e.g., stroke, epilepsy, encephalitis, sequelae of traumatic brain injury) or severe psychiatric disorder; (2) Coexistence of malignancy, severe hepatic or renal dysfunction, or long-term high-dose glucocorticoid use; (3) Presence of severe chronic systemic disease (e.g., end-stage cardiac insufficiency, end-stage pulmonary disease) or clear autoimmune disease; (4) Received radiotherapy or chemotherapy within the past 3 months; (5) Currently using immunosuppressants or biologics; (6) Pregnant or lactating females; (7) Other conditions deemed unsuitable for inclusion in the study by the investigator.

Design outcomes

Primary

MeasureTime frame
RBM15B levels in peripheral blood mononuclear cells;Routine laboratory tests: White blood cell count (WBC), hemoglobin (Hb), platelet count (PLT), C-reactive protein (CRP), serum albumin, AST, ALT, creatinine (Cr), estimated glomerular filtration rate (eGFR), and electrolytes.;Cognitive Function and SAE Assessment;

Countries

China

Contacts

Public ContactMo Yunchang

The First Affiliated Hospital of Wenzhou Medical University

myc1104@163.com+86 13736924260

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026